JP2009506063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506063A5 JP2009506063A5 JP2008528163A JP2008528163A JP2009506063A5 JP 2009506063 A5 JP2009506063 A5 JP 2009506063A5 JP 2008528163 A JP2008528163 A JP 2008528163A JP 2008528163 A JP2008528163 A JP 2008528163A JP 2009506063 A5 JP2009506063 A5 JP 2009506063A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- unsaturated
- groups
- aromatic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920006395 saturated elastomer Polymers 0.000 claims 72
- 125000000217 alkyl group Chemical group 0.000 claims 65
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 65
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims 56
- 125000003118 aryl group Chemical group 0.000 claims 56
- 229910052760 oxygen Inorganic materials 0.000 claims 55
- 229910052757 nitrogen Inorganic materials 0.000 claims 54
- 229910052717 sulfur Chemical group 0.000 claims 49
- 239000001301 oxygen Chemical group 0.000 claims 48
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 47
- 239000000651 prodrug Substances 0.000 claims 43
- 229940002612 prodrug Drugs 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 43
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 42
- 150000002148 esters Chemical class 0.000 claims 42
- 239000011593 sulfur Chemical group 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000005842 heteroatom Chemical group 0.000 claims 40
- 150000001204 N-oxides Chemical class 0.000 claims 31
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 229910052799 carbon Inorganic materials 0.000 claims 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 16
- 125000004429 atom Chemical group 0.000 claims 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000005841 biaryl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 108020004485 Nonsense Codon Proteins 0.000 claims 2
- 229910003849 O-Si Inorganic materials 0.000 claims 2
- 229910003872 O—Si Inorganic materials 0.000 claims 2
- 206010062255 Soft tissue infection Diseases 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000037434 nonsense mutation Effects 0.000 claims 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
- 206010040872 skin infection Diseases 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 208000037041 Community-Acquired Infections Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- GDIHDSKOVXEJQQ-UHFFFAOYSA-N NC(O)=O.NC(O)=O.NC(O)=O.N Chemical compound NC(O)=O.NC(O)=O.NC(O)=O.N GDIHDSKOVXEJQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- -1 said ring optionally Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *CC(C(*)[C@@]([C@]1*)N(*)CCc2c[n](**)nn2)O[C@@]1O* Chemical compound *CC(C(*)[C@@]([C@]1*)N(*)CCc2c[n](**)nn2)O[C@@]1O* 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71144005P | 2005-08-24 | 2005-08-24 | |
| US79792606P | 2006-05-05 | 2006-05-05 | |
| PCT/US2006/033157 WO2007025089A2 (en) | 2005-08-24 | 2006-08-24 | Triazole compounds and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009506063A JP2009506063A (ja) | 2009-02-12 |
| JP2009506063A5 true JP2009506063A5 (https=) | 2009-10-08 |
Family
ID=37631779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008528163A Withdrawn JP2009506063A (ja) | 2005-08-24 | 2006-08-24 | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US8470985B2 (https=) |
| EP (1) | EP1934237A2 (https=) |
| JP (1) | JP2009506063A (https=) |
| WO (1) | WO2007025089A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1723159B1 (en) | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
| EP1934237A2 (en) * | 2005-08-24 | 2008-06-25 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
| EP3290427A1 (en) | 2005-08-24 | 2018-03-07 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
| WO2008106204A1 (en) * | 2007-02-28 | 2008-09-04 | Rib-X-Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| CA2735773A1 (en) * | 2008-09-02 | 2010-03-11 | Neurosearch A/S | Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| JP6170064B2 (ja) * | 2011-11-25 | 2017-07-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 抗菌性チロシン誘導体およびその製造方法 |
| CN107205989A (zh) | 2014-11-14 | 2017-09-26 | 梅琳塔治疗公司 | 治疗、预防或降低皮肤感染风险的方法 |
| UA120571C2 (uk) | 2016-03-22 | 2019-12-26 | Мерк Шарп Енд Дохме Корп. | Алостеричні модулятори нікотинових ацетилхолінових рецепторів |
| US20240076293A1 (en) * | 2020-12-28 | 2024-03-07 | Georgia Tech Research Corporation | Compositions and Methods for Inhibiting Fibrosis, Inflammation and Cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY113693A (en) | 1992-05-26 | 2002-05-31 | Chugai Pharmaceutical Co Ltd | Erythromycin derivatives having an enterokinesis stimulating action |
| DE19604223A1 (de) * | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
| FR2748746B1 (fr) | 1996-05-14 | 1998-08-14 | Hoechst Marion Roussel Inc | Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine |
| BR9812577A (pt) | 1997-09-30 | 2000-10-17 | Abbott Lab | Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas |
| AR043071A1 (es) | 1997-10-31 | 2005-07-20 | Abbott Lab | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica |
| US6288234B1 (en) | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| HRP980646B1 (en) | 1998-12-30 | 2008-02-29 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | Novel oleandomycin derivatives |
| US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| KR20020072311A (ko) | 2000-02-10 | 2002-09-14 | 파마시아 앤드 업존 캄파니 | 피페라진 아미드 치환기를 갖는 옥사졸리디논 티오아미드 |
| GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| CA2429709A1 (en) | 2000-12-01 | 2002-07-04 | Gary Ashley | Motilide compounds |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| SI1427711T1 (sl) | 2001-09-11 | 2005-12-31 | Astrazeneca Ab | Oksazolidinonski in/ali izoksazolinski derivati kot antibakterijska sredstva |
| EP1443930A1 (en) | 2001-10-25 | 2004-08-11 | AstraZeneca AB | Isoxazoline derivatives useful as antimicrobials |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| TW200420573A (en) * | 2002-09-26 | 2004-10-16 | Rib X Pharmaceuticals Inc | Bifunctional heterocyclic compounds and methods of making and using same |
| WO2005042554A1 (en) | 2003-10-30 | 2005-05-12 | Rib-X Pharmaceuticals, Inc. | Bifunctional macrolide heterocyclic compounds and methods of making and using the same |
| US20070270357A1 (en) | 2003-11-18 | 2007-11-22 | Farmer Jay J | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same |
| EP1723159B1 (en) * | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
| WO2005118610A2 (en) * | 2004-06-01 | 2005-12-15 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| EP1934237A2 (en) * | 2005-08-24 | 2008-06-25 | Rib-X Pharmaceuticals, Inc. | Triazole compounds and methods of making and using the same |
| EP3290427A1 (en) | 2005-08-24 | 2018-03-07 | Melinta Therapeutics, Inc. | Triazole compounds and methods of making and using the same |
-
2006
- 2006-08-24 EP EP06802297A patent/EP1934237A2/en not_active Withdrawn
- 2006-08-24 WO PCT/US2006/033157 patent/WO2007025089A2/en not_active Ceased
- 2006-08-24 US US11/990,833 patent/US8470985B2/en not_active Expired - Fee Related
- 2006-08-24 JP JP2008528163A patent/JP2009506063A/ja not_active Withdrawn
-
2013
- 2013-06-14 US US13/918,344 patent/US9085600B2/en not_active Expired - Fee Related
-
2015
- 2015-06-26 US US14/751,625 patent/US20160152654A1/en not_active Abandoned
-
2017
- 2017-01-12 US US15/404,757 patent/US20170349621A1/en not_active Abandoned
-
2018
- 2018-08-08 US US16/058,352 patent/US20190211046A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116249683A (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| JP2019522055A5 (https=) | ||
| JP2009506075A5 (https=) | ||
| JP2009506066A5 (https=) | ||
| WO2016161361A4 (en) | Compositions and methods of targeting mutant k-ras | |
| WO2010031251A1 (zh) | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 | |
| JP2009506063A5 (https=) | ||
| US20140378409A1 (en) | Effect potentiator for antitumor agents | |
| CN118126040A (zh) | 含四氢吡唑并吡啶[3,4-d]嘧啶结构的化合物 | |
| EP2349275A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
| EP3528803A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| JP2007525520A5 (https=) | ||
| JP2012180344A5 (https=) | ||
| TW202002978A (zh) | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 | |
| CN110478487B (zh) | 一种大环内酯化合物在逆转肿瘤多药耐药增强抗肿瘤疗效方面的应用 | |
| KR20200084875A (ko) | 항균성 화합물 | |
| JP2022529212A (ja) | 経口送達されるベータ－ラクタマーゼ阻害剤の固体形態およびその使用 | |
| WO2005007143A2 (en) | Use of makrolides and ketolides for the treatment of tuberculosis | |
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| JP2025520237A (ja) | ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物 | |
| JP2012509313A5 (https=) | ||
| MX2011005003A (es) | Inhibidor de p70 s6 quinasa y terapia de combinacion de inhibidor de mtor. | |
| JP2007509980A5 (https=) | ||
| TW202241444A (zh) | 治療或預防波形蛋白介導的疾病的化合物 | |
| CA2739505A1 (en) | Anti-xdr-tb agent, anti-mdr-tb agent, and combined anti-tuberculosis agent |